Have you been diagnosed with pleural fluid, and have been referred for a pleural fluid drainage? If so, you may be able to participate in a research registry to help us learn more about lung cancer.

The purpose of this study is to understand how monitoring symptoms at home after lung cancer diagnosis could impact quality of care and the likelihood of returning to the hospital. This study will also help us understand whether symptom monitoring in patients with advanced lung cancer is helpful for patients and the clinical teams who care for them.

Have you been diagnosed with Advanced Prostate Cancer? If so, you may be able to take part in an International Registry for Men.

Have you ever been diagnosed with metastatic triple negative breast cancer and received 2 or less lines of chemotherapy for your metastatic disease? If so you may be eligible for a trial to evaluate different treatment combination with avelumab for your metastatic breast cancer.

Have you recently been diagnosed with breast cancer but have not yet started treatment (other than surgery)? You may be able to take part in the UNC CogMAP study. In this study, we want to learn more about cognitive and brain function before and after cancer treatment. This will help us to better understand risk factors for experiencing cognitive difficulties during and after treatment.

This study is assessing the effectiveness and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when given with atezolizumab and bevacizumab as a first-line treatment for unresectable, locally advanced or metastatic patients with hepatocellular carcinoma (HCC). TIGIT is thought to play an important role in HCC's response to immunotherapy treatments such as atezolizumab. This study will assess whether the addition of tiragolumab to atezolizumab and bevacizumab will improve response and clinical outcomes.

To evaluate the best overall response rate (BOR) of recurrent/metastatic androgen receptor positive (AR+) salivary gland cancer (SGC) patients with darolutamide and androgen deprivation therapy (ADT).

The purpose of this study is to test good and bad effects of different drugs against metastatic brain tumors with altered genes. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in brain metastases and have found several genes that are altered, or mutated. There are medications that target these genes. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your metastatic cancer. The usual approach is defined as care most people get for your metastatic cancer.

Have you been diagnosed with extremity soft tissue sarcoma and are scheduled to have standard of care radiotherapy (XRT) followed by surgery to treat your cancer? XRT is effective in managing extremity soft tissue sarcoma, however, it is associated with risks, such as damage to healthy tissue, and complications in post-surgery wound healing.

Did you have head or neck cancer? Have you completed radiation in the past 3 years or more and now have dry mouth? You may be able to take part in a research study to help us learn if a gene therapy can help people with dry mouth due to radiation therapy.